



SciTech Development, LLC

SciTech Development's Presentation Abstract for ASH 2019 Published

(GROSSE POINTE FARMS, MI) December 4, 2019 – [SciTech Development](#), a clinical stage drug development company, is pleased to announce that the abstract of its poster presentation for the Annual American Society of Hematology Meeting (ASH 2019) titled "A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma" has been published in the November 2019 supplement issue of Blood (Blood (2019) 134 (Supplement_1): 4041). To view the abstract, visit <https://doi.org/10.1182/blood-2019-127278>

The published abstract highlights SciTech's proposed clinical trial of ST-001 nanoFenretinide for the treatment of T-cell non-Hodgkin's lymphoma. SciTech's T-001 nanoFenretinide technology is a small-molecule cancer drug employing a nanoparticle suspension for intravenous administration. ST-001 is comprised of nanoparticle sized fenretinide in a patented combination with carefully selected non-toxic phospholipids. SciTech's product pipeline includes nanoFenretinide formulations for the treatment of several cancer indications.

The company has submitted an Investigational New Drug (IND) Application for ST-001 nanoFenretinide and the FDA has granted it Orphan Drug Status for the treatment of two types of non-Hodgkin's lymphoma (NHL): peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Information regarding SciTech's nano formulation technology and oncology drug product ST-001 nanoFenretinide is available from SciTech Development, LLC by calling +1-313-938-5517 or online at <https://www.scitechdevelopment.com/>.



About SciTech Development

SciTech Development, LLC is a clinical stage drug development company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with

laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | eth@scitechdevelopment.com

For More Information About SciTech: Earle T. Holsapple, President
SciTech Development, LLC
(313) 938-5517

Forward-Looking Information

This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. In particular, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.



####